Ken Griffin Applied Therapeutics Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 119,600 shares of APLT stock, worth $581,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,600

Previous 64,500 85.43%

Holding current value

$581,256

Previous $216,000 276.39%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.25 - $7.4 $167,631 - $551,322	-74,503 Reduced 95.99%	3,109 $21,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $142,119 - $258,750	77,239 Added 20707.51%	77,612 $260,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.77 $10,279 - $22,597	-8,158 Reduced 95.63%	373 $0
Q2 2023 Aug 14, 2023	BUY	$0.77 - $1.8 $6,568 - $15,355	8,531 New	8,531 $10,000
Q4 2022 Feb 14, 2023	BUY	$0.65 - $1.12 $243 - $418	374 New	374 $0

Q2 2022 Aug 15, 2022	BUY	$0.76 - $2.64 $47,240 - $164,097	62,158 Added 372.54%	78,843 $75,000
Q1 2022 May 16, 2022	BUY	$1.48 - $6.22 $8,919 - $37,487	6,027 Added 56.55%	16,685 $35,000
Q4 2021 Feb 14, 2022	SELL	$8.77 - $18.29 $21,582 - $45,011	-2,461 Reduced 18.76%	10,658 $95,000
Q2 2021 Aug 16, 2021	BUY	$14.05 - $25.04 $184,321 - $328,499	13,119 New	13,119 $272,000
Q3 2020 Nov 16, 2020	SELL	$19.43 - $35.36 $1.23 Million - $2.24 Million	-63,322 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.41 - $51.23 $665,548 - $1.16 Million	22,630 Added 55.61%	63,322 $2.29 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $55.47 $795,121 - $2.26 Million	40,692 New	40,692 $1.33 Million

Others Institutions Holding APLT

# of Institutions

100

Shares Held

94M

Call Options Held

5.83M

Put Options Held

231K

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $233M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account